Mettler-Toledo International Inc. — 2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019; U.S. GAAP unless noted. The filing was signed February 7, 2020. Figures below are in U.S. dollars.
Business context
Mettler-Toledo supplies precision instruments and related services, including laboratory and industrial weighing, analytical instruments, product inspection, process analytics, and food-retail solutions. Sales are diversified across more than 140 countries. Laboratory products and services represented 52% of 2019 sales, industrial 41%, and retail 7%. No single customer accounted for more than 1% of sales.
Key financial results
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Net sales | $3.009 billion | $2.936 billion | +2% reported; +5% in local currencies |
| Gross profit | $1.741 billion | $1.684 billion | Gross margin 57.9%, up from 57.4% |
| Earnings before taxes | $681.4 million | $651.9 million | +5% |
| Net earnings | $561.1 million | $512.6 million | +9% |
| Diluted earnings per share | $22.47 | $19.88 | +13% |
| Operating cash flow | $603.5 million | $565.0 million | +$38.4 million |
| Capital expenditures | $97.3 million | $142.7 million | Down $45.4 million |
| Cash and cash equivalents | $207.8 million | $178.1 million | +$29.7 million |
| Total debt | $1.291 billion | $1.035 billion | +$256.5 million |
Operating cash flow less capital expenditures was approximately $506 million. Year-end current assets were $1.110 billion and current liabilities $754.5 million. Reported working capital, excluding cash and short-term debt under the company’s definition, was $203.2 million. Total debt less cash was approximately $1.083 billion. The company reported $572.3 million available under its $1.1 billion revolving credit facility and compliance with debt covenants.
Material changes and quarterly performance
- Local-currency sales growth was 5%, compared with 6% in 2018; reported-dollar growth was 2%, compared with 8% in 2018.
- Laboratory sales grew 7% in local currencies, and industrial sales grew 4%. Food-retail sales declined 8% in local currencies, reducing total 2019 sales growth by about 1%.
- Service revenue grew 7% in local currencies. Service gross margin rose to 49.0% from 47.0%; product gross margin was 60.4%, versus 60.3%.
- Fourth-quarter 2019 sales were $844.0 million versus $817.9 million in 2018; net earnings were $192.7 million versus $181.2 million. Fourth-quarter diluted EPS was $7.84 versus $7.11.
- Chinese Operations’ external sales increased 4% in U.S. dollars, while segment profit fell 2%. U.S. Operations segment profit rose 30%.
Outlook, commentary, and risks
- Management provided qualitative growth priorities—market-share gains, emerging-market expansion, product innovation, margin improvement, and selective acquisitions—but this filing does not provide a clear quantified 2020 sales or EPS forecast.
- Management expected sales in China could decline in first-quarter 2020 because of the Wuhan coronavirus outbreak and related restrictions. The filing states that the scale and duration of the effect were uncertain.
- The company expected $15 million to $20 million of net investment in new manufacturing facilities in 2020. It estimated China-related tariffs added about $25 million in annualized costs at a 25% tariff rate; mitigation efforts were ongoing.
- 2019 gross-margin improvement reflected pricing and productivity, partly offset by tariffs and initial new-product costs. Restructuring charges were $15.8 million, primarily employee-related.
- The 2019 effective tax rate was 17.7%, including a $15.8 million non-cash net benefit from Swiss tax reform. The prior-year rate was 21.4% and included a $3.6 million U.S. tax-reform charge; 2018 also included a one-time $18.7 million Biotix contingent-consideration gain.
- Key exposures include China and other international markets, currency movements, tariffs and trade uncertainty, competition, supply and manufacturing interruptions, cybersecurity and IT-system risks, customer capital-spending cycles, and changing tax rules. The company had $165.5 million of cash in Chinese subsidiaries and noted regulatory requirements for converting and repatriating funds.
- The company estimated about $0.4 million of compliance costs over the next several years for a New Jersey groundwater site; it warned that additional environmental liabilities could arise. Management did not expect existing legal proceedings to have a material adverse effect.
- Share repurchases totaled $775 million in 2019, versus $475 million in 2018. At year-end, $1.3 billion remained authorized. The company has historically paid no common-stock dividends.
Most important facts for investors to verify
- Whether the anticipated China sales disruption and other trade-related risks affected 2020 results, and how actual performance compared with management’s qualitative outlook.
- Whether local-currency sales growth, laboratory and industrial demand, and food-retail recovery or weakness persisted after 2019.
- How debt, borrowing availability, interest costs, and share repurchases evolved; 2019 repurchases substantially exceeded capital expenditures.
- Whether pricing and productivity continued to offset tariff, investment, and cost pressures, and whether the Swiss tax benefit materially affected reported earnings comparisons.
- Whether pension, deferred-tax, environmental, and other estimates or contingencies changed. The auditor issued an unqualified opinion and found internal control over financial reporting effective; critical audit matters included lease adoption and deferred-tax valuation.